このページの翻訳は実験的なもので、現在開発中です。お待ちしております
GlycoMimetics 将来の成長
Future 基準チェック /26
GlycoMimeticsは、10.9%と72.8%でそれぞれ年率10.9%で利益と収益が成長すると予測される一方、EPSはgrowで27.8%年率。
主要情報
10.9%
収益成長率
27.8%
EPS成長率
Biotechs 収益成長 | 28.5% |
収益成長率 | 72.8% |
将来の株主資本利益率 | n/a |
アナリストカバレッジ | Low |
最終更新日 | 13 Sep 2024 |
今後の成長に関する最新情報
Recent updates
We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate
Jun 27GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17業績と収益の成長予測
日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
---|---|---|---|---|---|
12/31/2026 | 1 | -25 | -36 | -6 | 3 |
12/31/2025 | 4 | -31 | -37 | -8 | 3 |
12/31/2024 | N/A | -32 | -38 | -31 | 3 |
6/30/2024 | 0 | -39 | -36 | -36 | N/A |
3/31/2024 | 0 | -37 | -34 | -34 | N/A |
12/31/2023 | 0 | -37 | -35 | -35 | N/A |
9/30/2023 | N/A | -38 | -35 | -35 | N/A |
6/30/2023 | N/A | -37 | -35 | -35 | N/A |
3/31/2023 | 0 | -42 | -44 | -44 | N/A |
12/31/2022 | 0 | -47 | -47 | -46 | N/A |
9/30/2022 | 0 | -54 | -51 | -51 | N/A |
6/30/2022 | 0 | -63 | -60 | -60 | N/A |
3/31/2022 | 0 | -64 | -57 | -57 | N/A |
12/31/2021 | 1 | -63 | -58 | -57 | N/A |
9/30/2021 | 1 | -62 | -54 | -54 | N/A |
6/30/2021 | 2 | -58 | -49 | -49 | N/A |
3/31/2021 | 2 | -58 | -50 | -50 | N/A |
12/31/2020 | 10 | -51 | -39 | -39 | N/A |
9/30/2020 | 10 | -50 | -42 | -42 | N/A |
6/30/2020 | 9 | -50 | -44 | -44 | N/A |
3/31/2020 | 9 | -51 | -41 | -41 | N/A |
12/31/2019 | N/A | -58 | -52 | -52 | N/A |
9/30/2019 | N/A | -57 | -49 | -49 | N/A |
6/30/2019 | N/A | -55 | -46 | -46 | N/A |
3/31/2019 | N/A | -51 | -48 | -47 | N/A |
12/31/2018 | N/A | -48 | -43 | -43 | N/A |
9/30/2018 | N/A | -44 | -42 | -42 | N/A |
6/30/2018 | N/A | -40 | -38 | -38 | N/A |
3/31/2018 | N/A | -37 | N/A | -31 | N/A |
12/31/2017 | N/A | -33 | N/A | -30 | N/A |
9/30/2017 | N/A | -32 | N/A | -27 | N/A |
6/30/2017 | 0 | -32 | N/A | -29 | N/A |
3/31/2017 | 0 | -32 | N/A | -30 | N/A |
12/31/2016 | 0 | -32 | N/A | -30 | N/A |
9/30/2016 | 0 | -32 | N/A | -31 | N/A |
6/30/2016 | 0 | -32 | N/A | -10 | N/A |
3/31/2016 | 20 | -13 | N/A | -9 | N/A |
12/31/2015 | 20 | -13 | N/A | -8 | N/A |
9/30/2015 | 20 | -11 | N/A | -7 | N/A |
6/30/2015 | 20 | -11 | N/A | -26 | N/A |
3/31/2015 | 15 | -13 | N/A | -10 | N/A |
12/31/2014 | 15 | -11 | N/A | -4 | N/A |
9/30/2014 | 15 | -8 | N/A | -4 | N/A |
6/30/2014 | 15 | -5 | N/A | -2 | N/A |
3/31/2014 | 0 | -16 | N/A | -14 | N/A |
12/31/2013 | 4 | -11 | N/A | -16 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: GLYC今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: GLYC今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: GLYC今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: GLYCの収益 ( 71.7% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: GLYCの収益 ( 71.7% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: GLYCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です